BrainStorm Cell Therapeutics Inc.

<div class="infobox infobox-company">
<div class="infobox-header">BrainStorm Cell Therapeutics Inc.</div>
<div class="infobox-row"><strong>Headquarters:</strong> New York, New York, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2000</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (BCLI)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$50M USD</div>
</div>

Overview

<div class="infobox infobox-company">
<div class="infobox-header">BrainStorm Cell Therapeutics Inc.</div>
<div class="infobox-row"><strong>Headquarters:</strong> New York, New York, USA</div>
<div class="infobox-row"><strong>Founded:</strong> 2000</div>
<div class="infobox-row"><strong>Public:</strong> NASDAQ (BCLI)</div>
<div class="infobox-row"><strong>Market Cap:</strong> ~$50M USD</div>
</div>

Overview

BrainStorm Cell Therapeutics Inc. is a biotechnology company pioneering the development of autologous cell therapies for neurodegenerative diseases. The company's lead product, NurOwn®, is a personalized cell therapy derived from the patient's own bone marrow stromal cells (MSCs) that are engineered to secrete high levels of neurotrophic factors. BrainStorm's approach represents a novel therapeutic strategy that combines cell therapy with gene therapy concepts, using the patient's own cells as a manufacturing platform for delivering regenerative factors directly to the central nervous system["@brainstorm"].

The company focuses on diseases where neurotrophic factor deficiency plays a key role in disease progression, particularly amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease. BrainStorm's technology platform addresses a critical unmet need in neurodegenerative disease — the progressive loss of neuronal function due to reduced trophic support.

Technology Platform

MSC-NTF Cell Therapy

BrainStorm's proprietary technology platform, MSC-NTF (Mesenchymal Stromal Cells engineered to secrete NeuroTrophic Factors), represents a significant advancement in cell-based therapeutics:

• Cell Source: Autologous bone marrow-derived mesenchymal stromal cells from the patient
• Engineering Process: Cells are cultured under proprietary conditions that induce them to secrete elevated levels of neurotrophic factors including:
• Brain-Derived Neurotrophic Factor (BDNF)
• Glial Cell Line-Derived Neurotrophic Factor (GDNF)
• Vascular Endothelial Growth Factor (VEGF)
• Hepatocyte Growth Factor (HGF)
• Delivery Method: Intrathecal injection into the cerebrospinal fluid, allowing direct delivery to the spinal cord and brain

Mechanism of Action

The therapeutic benefit of NurOwn derives from multiple mechanisms:

Pipeline / Products

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| NurOwn (MSC-NTF) | Autologous MSC-NTF cells | ALS | Phase 3 | Completed |
| NurOwn | Autologous MSC-NTF cells | Progressive MS | Phase 1 | Active |
| NurOwn | Autologous MSC-NTF cells | [Alzheimer's Disease](/diseases/alzheimers-disease) | Preclinical | Planning |

Clinical Development

ALS (Amyotrophic Lateral Sclerosis)

NurOwn has undergone extensive clinical evaluation in ALS:

Phase 2 Trial (2018): An open-label, single-arm study demonstrated safety and suggested efficacy. Patients showed slower progression on the ALSFRS-R scale compared to historical controls, with responders identified as those maintaining or improving function[@nurown].

Phase 3 Trial (2020-2022): The pivotal Phase 3 trial enrolled approximately 200 patients with ALS at multiple U.S. sites. While the trial did not meet its primary endpoint of a statistically significant difference in response rate at 28 weeks, pre-specified subgroup analyses revealed clinically meaningful benefits in patients with less advanced disease (baseline ALSFRS-R ≥ 35). These patients showed significantly better outcomes in function, breathing, and quality of measures[@nurowna].

Multiple Sclerosis

BrainStorm is conducting an open-label Phase 1 trial evaluating NurOwn in patients with progressive forms of MS. The trial aims to assess safety and explore potential neuroprotective effects in a disease characterized by demyelination and neuronal loss.

[Alzheimer's Disease](/diseases/alzheimers-disease)

Preclinical studies have explored NurOwn in Alzheimer's disease models, demonstrating reduced neuroinflammation and improved cognitive function. The company has announced plans to advance this program based on these findings.

Funding & Financials

BrainStorm has pursued a strategic funding approach to support its clinical programs:

• 2000: Company founded
• 2014: Initial public offering on NASDAQ
• 2021: $15M public offering to support Phase 3 trial completion
• 2022: $30M registered direct offering for ongoing operations and pipeline development
• Current Market Cap: Approximately $50M USD (as of 2026)

Key People

• Dr. Ralph L. Kern (President & Chief Executive Officer) — Brings extensive experience in neuroscience drug development
• Dr. William J. R. Schmidt (Chief Medical Officer) — Oversees clinical development and regulatory strategy

Competitive Landscape

BrainStorm's cell therapy approach occupies a unique position in the ALS treatment landscape:

• Traditional Small Molecules: Riluzole and edaravone remain standard of care
• Novel Mechanisms: ASO therapies (e.g., tofersen for SOD1), antisense approaches
• Other Cell Therapies: Various companies exploring MSC-based approaches, though BrainStorm's MSC-NTF platform is most advanced
• Gene Therapy: AAV-based approaches targeting specific genetic mutations

Challenges and Future Directions

BrainStorm faces several challenges and opportunities:

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) (ALS)
• [Cell Therapy for Neurodegeneration](/therapeutics/cell-therapy-neurodegeneration)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [Mesenchymal Stem Cells](/therapeutics/mesenchymal-stem-cell-therapy)
• [ALS Treatment Pipeline](/companies/als-pipeline-companies)

References